/10.5772/56377 [28]Tonelli M, Lloyd A, Clement F, et al. for the Alberta Kidney Dia Network. Effica‐
cy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis;. CMAJ. 2011; 183(16): e1189–e1202.
[29]Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E,Hoogeveen RC, et al. Clinical
implications of JUPITER in a United States population: insights from the Atheroscle‐rosis Risk in Communities (ARIC) Study. J Am Coll Cardiol. 2009; 54(25): 2388–2395.
[30]Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-
Wende J, et al. Statin u and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.. Arch Intern Med. 2012; 172(2): 144-52.
[31]Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the develop‐
ment of new-ont type 2 diabetes: a meta-analysis of randomized controlled trials.
Curr Med Res Opin. 2008; 24(5): 1359-62.
[32]Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and
risk of incident diabetes: a collaborative meta-analysis of randomid statin trials.
Lancet. 2010; 375(9716): 735-42.
[33]Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident
diabetes with intensive-do compared with moderate-do statin therapy: a meta-analysis.. JAMA; 305(24): 2556-64.
[34]McEvoy JW. Statin therapy do and risk of new-ont diabetes. JAMA. 2011;
306(12):1325-6.
[35]American Heart Association statement on high-protein, low-carbohydrate diet study
prented at scientific ssions. American Heart Association press relea, Nov 19, 2012.
[36]Filippatos TD. A Review of Time Cours and Predictors of Lipid Changes with Fe‐
nofibric Acid-Statin Combination. Cardiovasc Drugs Ther. 2012 June; 26(3): 245–255.
[37]Uchechukwu K. Sampson, MacRae F. Linton, Sergio Fazio. Are statins diabetogenic?
Curr Opin Cardiol. 2011; 26(4): 342–347.
[38]The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabe‐
tes Mellitus. N Engl J Med. 2010; 362(17): 1563-74.
[39]Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination
with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Dia‐betes. 2012; 11(1):140.
[40]Carmena R, Betteridge DJ. Statins and diabetes. Semin Vas Med. 2004; 4 (4): 321-332.
[41]Heidmann C, Boeing H, Pischon T, Nothlings U, Joost HG, Schulze MB. Association
of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation
into Cancer and Nutrition (EPIC)-Potsdam cohort. Eur J Epidemiol. 2009; 24(6): 281-8.
[42]Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage DJ, et al. Trends
in all cau and cardiovascular dia mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation.
2009; 119(13): 1728-35.
[43]Lutufo PA, Gaziano M, Chae CU, Ajani UA, Moreno-John G, Buring JE, et al. Diabe‐
tes and all-cau and coronary heart dia mortality among US male physicians.
Arch Intern Med. 2001; 161(2): 242-7.
[44]Kanaya AM, Grady D, Barrett-Connor E. Explaining the x difference in coronary
heart dia mortality among patients with type 2 diabetes mellitus: a meta-analy‐sis. Arch Intern Med. 2002; 162(15); 1737-45.
[45]Young LH, Wackers FJ, Chyun DA, Davay JA, Barrett EJ, Taillefer R, et al. for DIAD
Investigators. Cardiac outcomes after screening for asymptomatic coronary artery dia in patient
s with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009; 301(15): 1547-55.
[46]Morrison JA, Glueck CJ, Horn PS, Schreiber GH, Wang P. Pre-teen insulin resistance
patients weight gain, impaired fasting gluco, and type 2 diabetes at age 18-19: a 10-y prospective study of black and white girls. Am J Clin Nutr. 2008; 88(3): 778-88. [47]Koska J, Ortega E, Bogardus C, Krakoff J, Bunt JC. The effect of insulin on net lipid
oxidation predicts worn of insulin resistance and development of type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2007; 293(1): 1264-1269.
[48]Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and
overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective obrva‐tional study. Diabetes Care. 2002; 25(5): 859-864.
[49]Cho E, RimmEB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus
and prior myocardial infarction on mortality from all caus and from coronary heart dia in men. J Am Coll Cardiol. 2002; 40(5): 954-60.
[50]Iglder B, Cip P, Malaimare L, Ladurner G, Paulweber B. The metabolic syndrome
is a stronger risk factor for early carotid atherosclerosis in women than in men.
Stroke. 2005; 36(6): 1212-7.
[51]Kawamoto R, Tomita H, Ohtsuka N, Inoue A, Kamitani A. Metabolic syndrome, dia‐
咸菜烧豆腐
betes and subclinical atherosclerosis as assd by carotid intima-media thickness. J Atheroscler Thromb. 2007; 14(2): 78-85.
[52]Bertoni A, Wong ND, Shea S, et al. Insulin resistance, metabolic syndrome, and sub‐
clinical atherosclerosis. The Multi-Ethnic Study of Atheroclerosis (MESA). Diabetes Care. 2007; 30: 2951-6.
/10.5772/56377 [53]Held C, Gerstein HC, Yusuf S, Ma S, Liu K, Preethi S, et al. for the ONTARGET/
TRANSCEND investigators. Gluco levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007; 115(11): 1371-5.
清廉中国
[54]Schulze MB, Hoffmann K, Boeing H, Linin J, Rothmann S, Mohilg M, et al. An
accurate risk score bad on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007; 30(3): 510-15.
水平仪的使用方法[55]Morrison JA, Glueck CJ, Umar M, Daniels S, Dolan LM, Wang P. Hyperinsulinemia
and metabolic syndrome at mean age of 10 years in black and white schoolgirls and development of impaired fasting gluco and type 2 diabetes mellitus by mean age of 24 years. Metabolism. 2011; 60(1): 24-31.
[56]Masuo K. Obesity-related hypertension: Role of sympathetic nervous system, insulin,
and leptin. Curr Hypertens Rep. 2002; 4(2): 112-8.
[57]Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanism of
sympathetic activation in obesity-related hypertension. Hypertension. 2006; 48(5): 787-96.
[58]Masuo k, Mikami H, Ogihara T, Tuck ML. Weight gain-induced blood pressure ele‐
vation. Hypertension. 2000; 35(5): 1135-40.
生活方面的自我评价
[59]Gentile CL, Orr JS, Davy BM, Davy KP. Modest weight gain is associated with sym‐
pathetic neural activation in nonobe humans. Am J Physiol Regul Interg Comp Phisiol. 2007; 292(5); R1834-38.
[60]Barnes MJ, Lapanowski K, Conley A, Rafols JA, Jen KL, Dunbar JC. High fat feeding
is associated with incread blood pressure, sympathetic nerve activity and hypo‐thalamic mu opioid receptors. Brain Res Bull. 2003; 61(5): 511-9.
[61]Anderson B, Elam M, Wallin BG, Bjorntorp P, Anderson OK. Effect of energy-re‐
stricted diet on sympathetic muscle nerve activity in obe women. Hypertension.
1991; 18(6): 783-9.
[62]Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestle PJ. Effects of
dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syn
drome. J Clin Endocrinol Met. 2005; 90(11): 5998-6005.
[63]Tuck ML, Sowers JR, Dornfeld L, Whitfield L, Maxwell M. Reductions in plasma cat‐
echolamines and blood pressure during weight loss in obe subjects. Acta Endocri‐nol (Copenh). 1983; 102(2): 252-7.
[64]Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, et al. Body
weight reduction, sympathetic nerve traffic, and arterial baroreflex in obe normo‐tensive humans. Circulation. 1998; 97(20): 2037-2042.
[65]Masuo K, Katsuya T, Ogihara T, Tuck ML. Acute hyperinsulinemia reduces plasma
leptin levels in insulin nsitive men. Am J Hypertens. 2005; 18(2 Pt 1): 235-43.
[66]Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DASG. Impact of
type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circula‐tion. 2003; 108(25): 3097-3101.
[67]Staznicky NE, Lambert GW, Masuo K, et al. Blunted sympathetic neural respon to
oral gluco in obe subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr. 2009; 89: 27-36.
[68]Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert EA, Nestel PJ, et al. Neuroa‐
drenergic dysfunction along the diabetes continuum: a comparative study in obe metabolic syndrome subjects. Diabetes. 2012; 61(10): 2506-16.
[69]Takatori S, Zamami Y, Mio M, Kurosaki Y, Kawasaki H. Chronic hyperinsulinemia
enhances adrenergic vasoconstriction and decreas calcitonin gene-related peptide-containing nerve-mediated vasodilation in pithed rats. Hypertens Res. 2006; 29(5): 361-368.
一周减肥食谱[70]Zamami Y, Takatori S, Yamawaki K, Miyashita S, Mio M, Kitamura Y, Kawasaki H.
Acute hyperglycemia and hyperinsulinemia enhance adrenergic vasoconstriction and decrea calcitonin gene-related peptide-containing nerve-mediated vasodilation in pithed rats. Hypertens Res. 2008(5); 31: 1033-1044.
[71]Gudbjornsdottir S, Elam M, Sellgren J, Anderson EA. Insulin increas forearm vas‐
cular resistance in obe, insulin-resistant hypertensives. J Hypertens. 1996; 14(1): 91-7.
[72]van Veen S, Frolich M, Chang PC. Acute hyperglycemia in the forearm induces vaso‐
dilation that is not modified by hyperinsulinemia. J Human Hypertens. 1999; 13(4): 263-68.
[73]Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin-aldoster‐
one system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012; 14(2): 160-9.
[74]Mar RE, Lenhard MJ, Kolm P, Edwards DG. Direct renin inhibition improves para‐
sympathetic function in diabetes. Diabetes Obes Metab. 2013; 15(1): 28-34. 2012 Jul
27. doi: 10.1111/j.1463-1326.
[75]Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention:
神经质症a Japane trial in IGT males. Diabetes Res Clin Pract. 2005; 67(2): 152-62.
[76]Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Effects of weight loss on re‐
nal function in overweight Japane men. Hypertens Res. 2011; 34(8): 915-21. [77]Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Cardiovascular and renal
complications of type 2 diabetes in obesity: role of sympathetic nerve activity and in‐sulin resistance. Curr Diabetes Rev. 2010; 6(2): 58-67.
/10.5772/56377 [78]Straznicky NE, Grima MT, Lambert EA, et al. Exerci augments weight loss induced
分手了别来打扰我improvement in renal function in obe metabolic syndrome individuals. J Hyper‐tens. 2011; 29(3): 553-64
[79]Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of
sympathetic nervous activity in renal injury and end-stage renal dia. Hypertens Res. 2010; 33(6): 521-8.
[80]Masuo K, Rakugi H, Ogihara T, Tuck ML. β1 (Arg389Gly, Ser49Gly)- and β2
(Arg16Gly)-adrenoceptor polymorphisms are related to left ventricular hypertrophy in middle-aged, nonobe,l normotensive men, but through different mechanisms.
Circulation. 2008; 18 (119) Suppl 2: S1154.
[81]Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S.
The effect of metformin and intensive lifestyle intervention on the metabolic syn‐drome: The Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;
142(8): 611-619.
[82]Andersn SA, Carroll S, Urdal P, Holme I. Combined diet and exerci intervention
revers the metabolic syndrome in middle-aged males: results from the Oslo Diet and Exerci Study. Scand J Med Sci Sports. 2007; 17(6): 687-95.
[83]Allison DB, Zannolli R, Faith MS, Heo M, Piethobelli A, Vanltallie TB, et al. Weight
loss increas and fat loss decreas all-cau mortality rate: results from two inde‐pendent cohort studies. Int J Obes Relat Metab Disord. 1999; 23(6): 603-11.
[84]Poobalan AS, Aucott LS, Smith WCS, Avenell A, Jung R, Broom J. Long-term weight
loss effects on all cau mortality in overweight/obe populations. Obes Rev. 2007;
8(6): 503-13.
[85]Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Nedei H, et al. Effects of
bariatric surgery on mortality in Swedish obe subjects. N Engl J Med. 2007; 357(8): 741-52.
[86]Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skiner S, et al. Adjusta‐
ble gastric banding and conventional therapy for type 2 diabetes: a randomized con‐trolled trial. JAMA. 2008; 299(3): 316-23.
浙江师范大学分数线[87]Sierra-Johnson J, Romeo-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires
RW, Allison TG. Prognostic importance of weight loss in patients with coronary heart dia regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil.
2008; 15(3): 336-40.
[88]Masuo K, Mikami H, Ogihara T, Tuck ML. Differences in mechanisms between
weight loss-nsitive and -resistant blood pressure reduction in obe subjects. Hy‐pertens Res. 2001; 24(4):371-6.
